Compare Royal Caribbean Cruises Ltd (RCL) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Caribbean Cruises Ltd vs Viatris Inc — how do they compare? Royal Caribbean Cruises Ltd trades at $281.01 (market cap $75.26B), while Viatris Inc trades at $17.22 (market cap $20.03B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 3.8× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Royal Caribbean Cruises Ltd for 85 Days and Viatris Inc for 57 Days on average.
| RCL | VTRS | |
|---|---|---|
Market Cap | $75.26B | $20.03B |
Volume | 1,958,628 | 14,109,977 |
Sector | Consumer Cyclical | Health |
52-Week High | $348.03 | $18.27 |
52-Week Low | $230.30 | $9.74 |
Typical Hold Time | 85 Days | 57 Days |
Enterprise Value | $97.91B | $32.15B |
Dividend Yield | 2.13% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royal Caribbean (RCL) trades at $282.36, down 2.25% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamental performance with Q1 and Q2 2026 earnings beats, revenue growth to $17.93B in 2025, and improving profit margins. Recent developments include a $3B investment in Sandals Resorts, expanding into the all-inclusive resort market. Analyst consensus remains positive with a $346.67 price target and 51% buy ratings.
RCL presents a compelling growth story with strong earnings momentum and strategic expansion, though investors face risks from high leverage, fuel cost volatility, and execution challenges from the Sandals acquisition. The stock's current valuation appears reasonable given growth prospects, but requires monitoring of debt levels and integration success.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows consistent earnings beats with Q2 2026 EPS of $0.69 exceeding expectations, while maintaining strong operational cash flow of $2.32B in 2025. Recent developments include FDA approval for WAKIX in Japan and continued recognition as a top employer.
Despite negative net margins, Viatris demonstrates improving cash flow trends and strategic portfolio optimization. The stock offers 27% upside to consensus price target of $22.17, though investors face risks from debt levels and competitive pressures in the generic drug market. Deleveraging progress and pipeline advancements support potential re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
